Abstract
Objective
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a significant global health concern, representing the leading cause of chronic liver disease and posing a substantial public health challenge. NAFLD is associated with higher insulin resistance (IR) levels, a key pathophysiological mechanism contributing to its development and progression. To counter this growing trend, it is crucial to raise awareness about NAFLD and promote healthy lifestyles to mitigate the impact of this disease.
Methods
Relevant studies regarding IR and NAFLD published until May 30, 2023, were extracted from Google PubMed, Scopus, and Web Of Science web databases. The following keywords were used: IR, diabetes mellitus, Non-alcoholic fatty liver disease, and metabolic syndrome.
Results
IR leads to an accumulation of fatty acids within liver cells, resulting from increased glycolysis and decreased apolipoprotein B-100. Furthermore, the manifestations of NAFLD extend beyond liver-related morbidity and mortality, affecting multiple organs and giving rise to various non-communicable disorders such as diabetes mellitus, metabolic syndrome, polycystic ovary syndrome, obstructive sleep apnea, and cardiovascular disease. Although lifestyle modification remains the primary treatment approach for NAFLD, alternative therapies, including pharmacological, herbal, and surgical interventions, may be considered. By implementing early and simple measures, cirrhosis, end-stage liver disease, and hepatocellular carcinoma can be prevented.
Conclusions
There is a clear association between NAFLD and elevated levels of IR. Several metabolic conditions, such as obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome, are closely interrelated with NAFLD and IR. Raising awareness about NAFLD and promoting a healthy lifestyle are crucial steps to reverse the impact of this disease.
Keywords: Insulin resistance, Metabolic Dysfunction-Associated Fatty Liver Disease, Metabolic syndrome, Non-alcoholic Fatty Liver Disease, Type 2 diabetes mellitus
Introduction
Steatosis hepatitis or fatty liver, is a frequently observed histological condition characterized by the accumulation of lipids in hepatocytes. While excessive alcohol consumption is a major contributing factor, it can also results from exposure to various toxins, jejunoileal bypass surgery, drugs, and underlying diseases such as morbid obesity, type 2 diabetes mellitus (T2DM), hyperlipidemia, and cachexia [1]. Insulin resistance (IR) plays a significant role in the development and progression of metabolism-related diseases, including T2DM, hypertension, tumors, and non-alcoholic fatty liver disease (NAFLD) [2]. NAFLD is rapidly becoming a significant global health concern, representing the leading cause of chronic liver disease and posing a substantial public health challenge [3]. The incidence rate of NAFLD has been estimated to be 46.9 cases per 1,000 person-years. The global prevalence of NAFLD in adults has been reported to be 32%, with a growing trend. Furthermore, studies have shown that the incidence of NAFLD is higher among males [4].
Recently, it has been proposed to rename NAFLD a metabolic dysfunction-associated steatotic liver disease (MASLD) based on the presence of overweight/obesity, T2DM, and evidence of so-called “metabolic dysregulation” [5]. However, NAFLD or MAFLD is a spectrum disorder that ranges from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), which can progress to liver fibrosis, cirrhosis, liver cancer, end-stage liver failure, and even death [6]. The pathophysiology of NAFLD involves two stages. The initial stage is characterized by insulin resistance (IR) and obesity, which lead to steatosis. In the second stage, oxidative stress triggers inflammation, ultimately resulting in the development of NASH, and exacerbates IR [2]. Lifestyle modifications are critical for managing non-alcoholic steatosis in patients [7]. Given the significance of raising awareness about NAFLD and its management to mitigate its impact, the objective of this review is to provide a comprehensive overview of the evidence, primarily based on systematic review studies, highlighting the role of IR and endocrine comorbidities associated with IR in the context of NAFLD.
Epidemiology
The incidence of NAFLD is increasing globally, with an estimated prevalence rate of 29.8% [8]. The highest prevalence of NAFLD was observed in Latin America at 44.37%, followed by the Middle East and North Africa (MENA) at 36.53% [9]. The global prevalence of NAFLD is projected to increase to 55.4% by 2040 [10].
The incidence of NAFLD is twice as high in men as in women, and its prevalence and severity tend to increase with age. Approximately 25.24% of individuals worldwide have been diagnosed with NAFLD through imaging, and among those who underwent liver biopsy for clinical reasons, the prevalence of NASH is around 59.10% [6].
NAFLD has several established risk factors, including obesity, T2DM, hypertension, dyslipidemia, and metabolic syndrome (MetS). MetS features are highly prevalent in NAFLD patients, and its components also contribute to an increased risk of developing NAFLD [11]. Obesity is the most common risk factor for NAFLD, with the entire spectrum of obesity, from overweight to severe obesity, being associated with NAFLD. A meta-analysis conducted in 2023 showed that the incidence of NAFLD was 69.99% among overweight individuals and 75.27% among those who were obese [3].
T2DM also shows a high prevalence of NAFLD, with a bidirectional association between the two conditions [12]. Compared to the general population, people with T2DM have over twice the incidence of NAFLD, with 55.5% of T2DM patients affected by NAFLD [13].
Types and pathophysiology
NAFLD encompasses a range of conditions, from simple fat accumulation in at least 5% of the liver cells to more severe forms such as NASH, cirrhosis, and hepatocellular carcinoma (HCC) [6]. However, intermediate patterns are becoming increasingly evident. An assessment of liver biopsy samples is necessary to accurately diagnose NAFLD and NASH, as no reliable non-invasive tests are available. The development and progression of NAFLD are multifactorial processes involving several factors. The "two-hit" hypothesis posits that the fat buildup in the liver caused by a sedentary lifestyle, high-fat diet, obesity, and IR is the first hit, rendering the liver more vulnerable to further damage from a second hit. The second hit triggers inflammatory reactions and fibrosis. Evidence from animal models of obesity supports this hypothesis, as mice accumulate fat in the liver but only develop inflammation and fibrosis after the second hit [14].
A bidirectional relationship exists between NAFLD and metabolic disorders such as obesity, T2DM, MetS, and dyslipidemia. This connection between NAFLD and MetS suggests that MetS increases the likelihood of developing NAFLD while treating NAFLD, and NASH may also improve certain MetS features [2]. IR, obesity with an increase in fat cell growth, and alterations in the gut microbiome can occur due to a combination of dietary patterns, environmental influences, and genetic factors [2]. In patients with NASH, both T2DM and a family history of the condition are closely linked to higher severity of fibrosis. T2DM, in particular, increases the risk of cirrhosis and related complications. Meanwhile, lipids stored in adipocytes enhance the release of several adipokines to regulate insulin sensitivity and glucose levels in the liver, thereby inducing a higher incidence of T2DM [11].
Emerging evidence suggests that the gut microbiota impacts hepatic carbohydrate and lipid metabolism and the balance between pro-inflammatory and anti-inflammatory factors in the liver, directly affecting the progression of NAFLD to NASH [15]. Additionally, a specific genetic variation, the single-nucleotide polymorphism (SNP) rs738409 in the PNPLA3 gene, correlates with a higher likelihood of developing NAFLD/NASH [16]. Epigenetic examples related to NAFLD have been observed during the embryo development stage [17].
The most significant epidemiological factor for NAFLD, NASH, and fibrosis is aging [7]. However, the impact of gender on the prevalence of NAFLD remains unclear [18]. A sedentary lifestyle and social affluence are additional factors that contribute to NAFLD [19]. Economic globalization has led to changes in dietary habits, including increased consumption of carbohydrates, animal proteins, refined sugars, and additives, which contribute to the development of NAFLD [20]. This imbalance of energy can result in an increase in obesity and IR, both of which are contributing factors to NAFLD [21]. Smoking has also been linked to accelerated disease progression and advanced fibrosis in NAFLD [22]. Studies on the harmful effects of air pollutants suggest they play a crucial role in developing NAFLD [23]. Glucocorticoids, amiodarone, methotrexate, estrogens, tamoxifen, nonsteroidal anti-inflammatory drugs, and metoprolol are drugs that have been found to cause liver steatosis [24] (Table 1).
Table 1.
Risk factors leading to NAFLD (MASLD)
| Risk factors | Reference |
|---|---|
| Metabolic disorders like obesity, diabetes mellitus, MetS, dyslipidemia, IR, and imbalance of energy | [2, 11, 17–21] |
| Gut microbiota | [15] |
| Genetic | [16] |
| Epigenetic like harmful intrauterine environment | [17] |
| Age | [7] |
| Gender | [18] |
| Sedentary lifestyle | [19] |
| Social affluence | [19] |
| Changes in dietary habits like a high-fat diet | [20, 21] |
| Smoking | [22] |
| Air pollutants | [23] |
| medications like glucocorticoids, amiodarone, and methotrexate | [24] |
Mets: Metabolic syndrome; IR: Insulin resistance
Role of insulin resistance in NAFLD
NAFLD (MASLD) is linked to higher levels of IR, and the severity of steatosis also increases with IR, Figure 1. IR results in reduced glucose uptake and hyperglycemia. IR impedes insulin's anti-lipolytic action in the adipose tissue, leading to an increased release of Free Fatty Acids (FFA) [2]. High levels of insulin, glucose, and FFA levels impair fatty acid oxidation and promote hepatic fatty acid and triglyceride (TG) uptake, de novo lipid synthesis, and CCAAT/enhancer binding protein (C/EBP) expression. IR increases intra-hepatocytic fatty acids via increased glycolysis and decreased apolipoprotein B-100, preventing very low-density lipoprotein cholesterol (VLDL-C) export. The imbalance between pro-insulin, adiponectin, and anti-insulin; Tumor necrosis factor-alpha (TNF-α) cytokines secreted by adipose tissue likely causes IR development in NAFLD. Excess FFA both results from and contribute to IR. NAFLD patients show increased IR in muscles, the liver, and adipose tissue, which plays a significant role in NAFLD pathogenesis [25]. Peripheral lipolysis increases in adipose tissue, delivering more FFAs to the liver, causing de novo lipogenesis. Lipid overload in pancreatic β-cells leads to dysregulated insulin secretion, changes in Peroxisome proliferator-activated receptor alpha (PPAR-α), glucokinase, the glucose transporter-2, pre-proinsulin, and pancreatic duodenal homeobox-1 expression, resulting in FFA-induced β-cell apoptosis and IR. Although insufficient evidence exists to demonstrate a consistent association between any particular adipokine type and the histological severity of NAFLD, IR in the liver can cause dyslipidemia and increase atherosclerosis risk [2, 26].
Fig. 1.
Schematic role of insulin resistance in NAFLD and the co-morbidities associated with IR in NAFLD
Co-morbidities associated with IR in NAFLD patients
NAFLD manifestation extends beyond liver-related morbidity and mortality, systematically leading to several disorders summarized in Fig. 1.
Metabolic syndrome (MetS)
About 90% of individuals with NAFLD have multiple components of MetS, and about one-third meet the criteria for a diagnosis of MetS [2]. The underlying mechanism of NAFLD involves fat accumulation in the liver as TG. IR plays an important role in this process by facilitating the transport of free fatty acids from visceral fat stores or peripheral lipolysis into the liver. Several metabolic conditions, such as obesity, IR, T2DM, dyslipidemia, and hypertension, are closely linked with NAFLD [27].
Type 2 diabetes mellitus
Globally, 55.5% of patients with T2DM have NAFLD [12]. Additionally, when patients with T2DM also have NAFLD, their mortality rate is twice as high, and the risk of macro- and microvascular complications associated with diabetes increases [13, 28]. The development of both T2DM and NAFLD shares a common disease mechanism known as IR, and the severity of NAFLD is directly related to the occurrence of T2DM [29].
Dyslipidemia
Dyslipidemia is a common occurrence in patients with NAFLD, with a prevalence of 20-80% [30]. Patients with T2DM, MetS, and obesity often experience changes in their serum lipid levels, indicating a close link between these conditions and NAFLD. Atherogenic dyslipidemia, which is characterized by high levels of TGs, low levels of high-density lipoprotein cholesterol (HDL-C), and high levels of low-density lipoprotein cholesterol (LDL-C), is the most common form of dyslipidemia in NAFLD patients [31]. IR plays a role in increasing the flux of FFA in the body. This increase in FFA levels can lead to an increase in TG and VLDL-C production, as well as oxidative stress and lipid peroxidation - all of which are closely linked with the development of NAFLD [32].
Obesity
A meta-analysis conducted in 2023 demonstrated that the occurrence of NAFLD was 69.99% and 75.27% among overweight and obese individuals, respectively. Obesity is a major risk factor for developing MetS and related conditions [3].
Cardiovascular disease
NAFLD is commonly accompanied by classical risk factors for cardiovascular disease (CVD), such as IR, hypertension, atherogenic dyslipidemia, and obesity, and it is the leading cause of death among NAFLD patients [33]. Although the exact pathway in which NAFLD causes CVD is not entirely understood, some factors have been suggested. One possible explanation is that NAFLD leads to inflammation throughout the body, which damages the walls of blood vessels and results in plaque buildup and narrowing of arteries. Individuals with NAFLD also tend to have high levels of triglycerides and LDL-C secondary to IR, which are risk factors for CVD. Other potential mechanisms connecting NAFLD to CVD include oxidative stress, endothelial dysfunction, and changes in gut microbiota composition [34]. The effects of NAFLD on coronary atherosclerosis impact the heart and increase the risk of cardiomyopathy, cardiac valve calcification, and arrhythmia [35].
Polycystic ovary syndrome (PCOS)
Several studies have indicated that women with PCOS are at a higher risk of developing NAFLD. A recent meta-analysis estimated a 3.3-fold higher risk for women with PCOS. However, the analysis found no link between PCOS and NAFLD in patients who did not show signs of hyperandrogenism [36]. In women with PCOS, the development of NAFLD is associated with several factors, including IR, high levels of male hormones (hyperandrogenemia), obesity, dysfunctional fat tissue, and inflammation. Other potential factors include an imbalanced gut microbiome, mitochondrial function problems, and endocannabinoid system dysregulation [37]. Around 50% to 70% of women with PCOS have IR, which could contribute to the hyperandrogenism responsible for the symptoms of PCOS [38].
Other co-morbidities
Chronic kidney disease (CKD)
The likelihood of developing CKD is higher when NAFLD is present, and enhancing liver health can lead to better kidney function [39].
Obstructive sleep apnea (OSA)
OSA, characterized by low oxygen levels, can be a significant factor in the development of NAFLD and liver fibrosis progression [40]. A meta-analysis has found a clear link between OSA and MetS. However, the causality between these two factors has yet to be established. The preferred treatment for OSA is continuous positive airway pressure (CPAP), which could potentially slow down or prevent liver damage by effects on IR and oxidative stress. However, it is necessary to undergo treatment for at least three months [41].
Osteomalacia and osteoporosis
Patients with chronic liver disease, especially in the end stages, often experience osteomalacia and osteoporosis. These conditions are collectively known as "hepatic osteodystrophy." Although there is ample evidence linking NAFLD and osteoporosis, the exact relationship between the two has yet to be fully established. Further clinical studies are necessary to determine the best course of treatment for patients in this group [42].
Thyroid disorders
A meta-analysis showed that the prevalence of hypothyroidism among NAFLD patients ranged from 15.2% to 36.3% [43]. The development of NAFLD due to hypothyroidism is caused by an increase in LDL-C and the buildup of triglycerides in the liver tissue. This buildup of lipids can lead to inflammation and oxidative stress in the liver. Leptin may also affect the relationship between the thyroid and the liver [44]. Recently, a link between IR and hypothyroidism has been shown due to the effects of thyroid hormones on peripheral tissues [45].
Cancers
As NAFLD advances to steatohepatitis and cirrhosis, the probability of developing HCC also increases [46]. The liver-related and cancer-related mortality are among the top three causes of death in subjects with NAFLD. Given the growing epidemic of obesity, the incidence of NAFLD-related HCC has been shown to increase at a 9% annual rate [47]. Patients with NAFLD-related HCC are older, have a shorter survival time, and more frequently have heart disease [6].
In NAFLD, extrahepatic cancers are more common than HCC by over eightfold, and they are not linked to the stage of liver fibrosis. The types of extrahepatic cancers that occur most frequently include uterine, breast, prostate, colorectal, and lung [48].
Diagnosis and treatment of NAFLD
Screening in high-risk groups
Given the multi-factorial nature of NAFLD and its associations with other conditions such as diabetes, MetS, and chronic inflammation, adopting a holistic approach to treat NAFLD with a focus on IR appears crucial. It can be argued that there should be systematic screening for NAFLD, at least among higher-risk individuals with T2DM or obesity. Patients with T2DM have a higher prevalence of NAFLD, and the available evidence suggests a higher prevalence of NASH and advanced stages of fibrosis among T2DM. A cost-effective analysis suggests that screening for NASH in diabetes is ineffective because of the disutility associated with available treatment [49].
American Association for the Study of Liver Diseases (AASLD) and American College of Gastroenterology (ACG) guidelines statements [6]:
Routine Screening for NAFLD in high-risk groups attending primary care, diabetes, or obesity clinics is not advised at this time because of uncertainties surrounding diagnostic tests and treatment options, along with a lack of knowledge about the long-term benefits and cost-effectiveness of screening.
There should be a high index of suspicion for NAFLD and NASH in patients with T2DM.
Diagnosis
It is recommended that individuals who are at a high risk of developing NAFLD should undergo screening in an outpatient setting. The diagnosis of fatty liver disease involves a combination of the patient's medical history, physical examination, blood tests, and imaging techniques such as ultrasound, CT scan, or MRI to view the liver. In some cases, a liver biopsy may also be performed to obtain a sample for further analysis [6].
Treatment
The primary treatment step for patients with NAFLD should involve modifying their lifestyle, such as exercise, weight loss, and quitting smoking. In addition to dietary changes, engaging in physical activity is recommended for preventing NAFLD [7]. Early use of pharmaceutical treatments such as insulin sensitizers and lipid-lowering agents is also important [50]. The treatment summary is demonstrated in Table 2.
Table 2.
Treatment components of NAFLD (MASLD)
| Treatment types | Examples |
|---|---|
| Lifestyle modifications | Diet changes, |
| Exercise | |
| Weight loss | |
| Quitting smoking | |
| Medications | Anti-diabetic drugs, lipid-lowering agents |
| Natural products and supplementary therapies | Probiotics, prebiotics, omega-3, vitamin D, vitamin E, saffron |
| Surgery | Bariatric surgery, liver resection, and liver transplantation |
Lifestyle modifications
To treat NAFLD, lifestyle modifications are recommended [7].
Weight loss
Weight loss is particularly important in improving the histological features of NASH, with an energy-restriction diet consisting of low calories, low fat, and low carbs being suggested [51]. The Mediterranean diet is the most effective option for reducing cardio-metabolic risk factors and weight [52]. Consuming a whole grains diet can lower liver enzymes and improve liver steatosis [53]. A high-protein diet (over 30% protein) accompanied by restricting calories has a bigger effect on decreasing the levels of fat in the liver and oxidative stress compared to a low-protein diet (10% protein) [54].
Gradual weight loss is preferred, which can prevent the adverse effects of NASH [55]. Various guidelines recommend structured programs aimed at promoting healthy habits, with 7% to 10% weight loss being the common target [56]. A meta-analysis showed that losing weight was safe, and there is a correlation between the amount of weight loss and an improvement in the histology of NASH. However, over 50% of patients still need to reach their weight loss goals [57].
Physical activity
Exercise improves cardiovascular health and reduces IR and hepatic and visceral fat, but it is still unclear if it exerts independent benefits on NAFLD [58]. Limited data suggest that aerobic exercise may result in greater hepatic fat reduction than resistance training, and this effect may be independent of weight loss [28, 59]. However, the specific intensity and duration of exercise required to improve NAFLD must be better defined. A retrospective study showed that only participants in the highest-intensity exercise group had a significant hepatic fat reduction and improved metabolic parameters [60].
Natural products and supplementary therapies
A meta-analysis demonstrated that supplementation of curcumin has a beneficial impact leading to lower levels of liver enzymes in the blood and decreased total cholesterol and BMI in NAFLD [61].
While probiotics, prebiotics, and other microbiota modulators may not have direct healing effects, they can be a valuable supplementary treatment option for NAFLD and related conditions. They can help improve the intestinal barrier to prevent the formation of harmful liver-toxic metabolites or positively affect the immune system [62]. A meta-analysis demonstrated that probiotics are the most effective treatment option compared to the Mediterranean diet, curcumin, exercise, and lifestyle advice for improving indicators of NAFLD [63].
Supplementation with omega-3 benefits patients with NAFLD, and a thesis suggests that taking omega-3 fatty acids and phytosterol ester together is more effective in improving the condition than taking them individually [64]. Low levels of vitamin D have been connected to NAFLD development, so supplementing with this nutrient may be needed for NAFLD treatment [65]. Vitamin E is generally considered safe, but questions about its safety have been raised [66]. Saffron has also positively affected oxidative stress and inflammation [67]. Furthermore, zinc supplementation has been proven to improve IRS and provide antioxidative benefits, making it a potential therapy for NAFLD [68]. Also, research has shown that chromium can protect against liver injury, manage lipid levels, and improve IR [69].
Numerous studies have verified the effectiveness of herbal medicines and natural products in treating NAFLD. Livogen Plus® is a nutraceutical that includes various ingredients, such as bergamot polyphenolic fraction, curcumin complex, omega-3 PUFAs, artichoke leaf extract, black seed oil from Nigella sativa, pricoliv sourced from Picrorhiza kurroa, glutathione, S-adenosyl-l-methionine, and other natural components. These substances have been shown to have advantageous effects on NAFLD [70, 71]. In proper quantities and taken over a moderate to long-term period, Silymarin, Vitamin E, Vitamin D, Omega-3 Polyunsaturated Fatty Acids, Coenzyme Q10, Berberine, and Curcumin, when combined with lifestyle modifications, have beneficial outcomes for NAFLD and related indicators [72].
Medications
Anit-diabetic medications
The potential solution for treating NAFLD involves better management of glucose levels. One treatment option for NAFLD in patients with T2DM is sodium-glucose co-transporter-2 inhibitors (SLGT2i), which improve glycemic control and reduce visceral fat and weight, improving liver steatosis and fibrosis [73]. While most studies have focused on the effectiveness of SGLT2 inhibitors in patients with both T2DM and NAFLD, empagliflozin has been proven to improve hepatic states even in those without diabetes [74]. Another group of antidiabetic drugs, known as dipeptidyl peptidase-4 inhibitors (DPP-4I), like evogliptin, has shown potential in treating hepatic fibrosis and inflammation by improving inflammatory signaling pathways via the modulation of autophagy [75]. Glucagon-like peptide-1 receptor agonists (GLP-1RA), such as exenatide and liraglutide, have also demonstrated positive effects in reducing liver steatosis and fibrosis indices, as well as improving lipid profiles, anthropometric parameters, and hepatic fat content [76]. Finally, insulin continues to be essential in managing diabetes and NAFLD due to their interconnected pathways [77].
Although a meta-analysis found that thiazolidinediones effectively improved steatosis and inflammation, its common adverse effect is weight gain of 3 to 5 kg, postmenopausal bone loss, and increased risk of bladder cancer. It should not be given to patients with heart failure [57, 78]. According to the results of a network meta-analysis that compared the effectiveness of various anti-diabetic medications on non-diabetic NAFLD, Rosiglitazone and Vildagliptin were the most effective in improving ALT and AST levels, respectively, in patients with NAFLD who do not have diabetes [79].
Other medications
Pentoxifylline and obeticholic acid have demonstrated histological benefits in reducing hepatic fibrosis. However, there are no FDA-approved treatments for NASH, and none has shown efficacy in more than 50% of patients [80, 81].
Cardiovascular disease remains the leading cause of death in patients with NAFLD, even after liver transplantation. Therefore, lifestyle changes and management of comorbidities should be prioritized. Statins can be safely prescribed to patients with liver disease based on established guidelines [82]. Lipid-controlling medications such as pemafibrate, saroglitazar, and a combination of ezetimibe and rosuvastatin have been proven as NAFLD therapy [83].
A combination of vitamin E and hydroxytyrosol was effective in NAFLD treatment by improving IR and reducing hepatic fat levels through lowering inflammatory factors [84].
Ursodeoxycholic acid (UDCA) is known to have protective effects on the liver and act as an antioxidant [85].
The recombinant human growth hormone somatropin reduces liver fat and improves metabolic and cardiovascular complications [86]. Melatonin has also been identified as a potential treatment option for NAFLD [87].
In patients who undergo pancreatoduodenectomy, the development of NAFLD has been identified as a potential side effect. High-dose administration of digestive enzymes could be used as a preventive measure for these patients with exocrine pancreatic disability [88].
Studies have shown that lubiprostone, a laxative medication, helps treat NAFLD. However, further research is needed to determine its effectiveness in patients without constipation [89].
New modern and alternative medications/treatments
A meta-analysis by Li et al. predicts that bicyclol can be a new treatment for NAFLD therapy in the upcoming years [90].
Inhibitors of fatty acid synthase, such as TVB-2640 have been proven to reduce liver fat and hepatic de novo lipogenesis [91].
PXL770 treatment, which activates adenosine-monophosphate-activated protein kinase (AMPK), has shown positive metabolic effects and can be a therapeutic strategy for NAFLD, but more research is needed [92].
A ketohexokinase inhibitor, PF-06835919, is safe and effective in reducing hepatic steatosis and liver enzymes and has beneficial effects on cardiometabolic factors [93].
Low-molecular fucoidan (LMF) may also be useful in alleviating hepatitis and liver fibrosis [94].
There is a safe and effective therapy for NAFLD patients called combined metabolic activator (CMA), which is made up of L-carnitine tartrate, L-serine, N-acetyl-L-cysteine, and nicotinamide riboside [95]. On the other hand, some studies have not shown any improvement in NAFLD patients treated with L-carnitine [96].
Electroacupuncture treatment, which involves small needles with electrical potential connected to a stimulator, efficiently reduces NAFLD markers [97].
Surgery
Surgery is often the only effective treatment for NAFLD-associated end-stage liver disease and HCC. Different surgical procedures such as bariatric surgery, liver resection, and liver transplantation have demonstrated positive outcomes in NAFLD patients [98]. Bariatric and metabolic surgery, such as sleeve gastrectomy and Roux-en-Y gastric bypass, have also been explored to treat NAFLD by reducing weight [99].
Hydrothermal duodenal mucosal resurfacing (HDMR) is a medical procedure that involves lifting and removing the mucosa of the duodenum with an endoscope. It results in improving glycemic control and reducing liver steatosis [100].
Guidance statements for treatment of NAFLD
A summary of the guidance statements of AASLD and ACG guidelines for the treatment of NAFLD is [101]:
-The management of NAFLD should include treating liver disease and its associated metabolic comorbidities, such as obesity and T2DM.
-Weight loss is the key to improving the histopathological features of NASH.
-Weight loss generally reduces HS, which can be achieved either by a hypocaloric diet alone or in conjunction with increased physical activity.
-Exercise alone in adults with NAFLD may prevent or reduce HS, but its ability to improve other aspects of liver histology remains unknown.
-Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.
Conclusions
The global incidence of NAFLD (or MASLD) is increasing. There is a clear link between NAFLD and IR, and the severity of NAFLD is worsened by the presence of IR. Since several metabolic conditions are closely related to NAFLD and IR, targeting lifestyle modifications and IR plays a critical role in mitigating NAFLD progression. Raising awareness of the general population and healthcare providers could be crucial steps in addressing the impact of this disease. Primary care physicians, endocrinologists, and other specialists should be aware of NAFLD's extent and long-term effects. It means taking action early in a multidisciplinary approach can prevent the progression of cirrhosis, end-stage liver disease, and HCC. Further studies in this area are recommended to enhance our understanding of different aspects of NAFLD and ultimately reduce morbidity and mortality associated with the disease. Long-term follow-up studies would be valuable in clarifying clinical implications and informing appropriate diagnostic evaluation, follow-up protocols, and optimal treatment for NAFLD.
Abbreviations
- AASLD
American Association for the Study of Liver Diseases
- ACG
American College of Gastroenterology
- AMPK
Adenosine-monophosphate-activated protein kinase
- C/EBP
CCAAT/enhancer binding protein
- CKD
Chronic kidney disease
- CMA
Combined metabolic activator
- CVD
Cardiovascular disease
- DPP-4I
Dipeptidyl peptidase-4 inhibitors
- FFA
Free fatty acids
- GLP-1RA
Glucagon-like peptide-1 receptor agonists
- HCC
Hepatocellular carcinoma
- HDL-C
High density lipoprotein cholesterol
- HDMR
Hydrothermal duodenal mucosal resurfacing
- IR
Insulin resistance
- LDL-C
Low density lipoprotein cholesterol
- LMF
Low-molecular fucoidan
- MASLD
Metabolic dysfunction-associated steatotic liver disease
- MENA
Middle East and North Africa
- MetS
Metabolic syndrome
- NAFLD
Non-alcoholic fatty liver disease
- NASH
Non-alcoholic steatohepatitis
- OSA
Obstructive sleep apnea
- PCOS
Polycystic ovary syndrome
- PPAR-α
Peroxisome proliferator-activated receptor-alpha
- SNP
Single-nucleotide polymorphism
- T2DM
Type 2 diabetes mellitus
- TG
Triglyceride
- TNF-α
Tumor necrosis factor-alpha
- UDCA
Ursodeoxycholic acid
- VLDL-C
Very low density lipoprotein cholesterol
Authors’ contributions
OTM and AM conceived, coordinated the study, and equally contributed as corresponding authors. OTM and BL participated in design of the study. FZ, MM, AM, and OTM wrote draft the manuscript. MM, SHE, OTM, AM and BL helped to edit of the manuscript draft. All authors read and approved the final manuscript.
Data availability
Not applicable.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interest
All authors declare that there are no conflicts of interest.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Fateme Ziamanesh and Mehdi Mohammadi equally contributed as first authors.
Contributor Information
Ozra Tabatabaei-Malazy, Email: tabatabaeiml@sina.tums.ac.ir.
Asieh Mosallanejad, Email: mosalla.dr@gmail.com.
References
- 1.Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol. 1998;15(4):246–58. [PubMed]
- 2.Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. International Journal Molecular Sciences. 2021;22(20). [DOI] [PMC free article] [PubMed]
- 3.Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30. doi: 10.1016/S2468-1253(22)00317-X. [DOI] [PubMed] [Google Scholar]
- 4.Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61. 10.1016/S2468-1253(22)00165-0. [DOI] [PubMed]
- 5.New NAFLD Nomenclature. Avaiable at: https://www.aasld.org/new-nafld-nomenclature. Last updated: Sep.7. 2023.
- 6.Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi: 10.1002/hep.29367. [DOI] [PubMed] [Google Scholar]
- 7.Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama. 2015;313(22):2263–2273. doi: 10.1001/jama.2015.5370. [DOI] [PubMed] [Google Scholar]
- 8.Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–17.e28. doi: 10.1016/j.cgh.2021.12.002. [DOI] [PubMed] [Google Scholar]
- 9.Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clinical and molecular hepatology. 2022;28(4):841–850. doi: 10.3350/cmh.2022.0239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864. doi: 10.1053/j.gastro.2020.01.052. [DOI] [PubMed] [Google Scholar]
- 12.Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surgery for Obesity and Related Diseases. 2015;11(1):137–141. doi: 10.1016/j.soard.2014.06.015. [DOI] [PubMed] [Google Scholar]
- 13.Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi: 10.1016/j.jhep.2019.06.021. [DOI] [PubMed] [Google Scholar]
- 14.Day CP, James OF. Steatohepatitis: a tale of two “hits”? : Elsevier; 1998. p. 842–5. [DOI] [PubMed]
- 15.Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787–1794. doi: 10.1136/gutjnl-2012-303816. [DOI] [PubMed] [Google Scholar]
- 16.Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, Ueno T, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Medical Genetics. 2010;11(1):172. doi: 10.1186/1471-2350-11-172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD risk. Molecular Metabolism. 2021;50:101111. doi: 10.1016/j.molmet.2020.101111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, De Klerk N, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology. 2011;53(3):800–809. doi: 10.1002/hep.24097. [DOI] [PubMed] [Google Scholar]
- 19.Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519–1523. doi: 10.1126/science.1204265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Alferink LJ, Kiefte-de Jong JC, Erler NS, Veldt BJ, Schoufour JD, de Knegt RJ, et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. Gut. 2019;68(6):1088–1098. doi: 10.1136/gutjnl-2017-315940. [DOI] [PubMed] [Google Scholar]
- 21.Rocha R, Cotrim HP, Carvalho F, Siqueira A, Braga H, Freitas L. Body mass index and waist circumference in non-alcoholic fatty liver disease. Journal of human nutrition and dietetics. 2005;18(5):365–370. doi: 10.1111/j.1365-277X.2005.00634.x. [DOI] [PubMed] [Google Scholar]
- 22.Azzalini L, Ferrer E, Ramalho LN, Moreno M, Domínguez M, Colmenero J, et al. Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology. 2010;51(5):1567–1576. doi: 10.1002/hep.23516. [DOI] [PubMed] [Google Scholar]
- 23.Kumar R, Prakash S, Chhabra S, Singla V, Madan K, Gupta SD, et al. Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. The Indian journal of medical research. 2012;136(2):229. [PMC free article] [PubMed] [Google Scholar]
- 24.Kolaric TO. Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, et al. Drug-induced fatty liver disease: Pathogenesis and treatment. Journal of Clinical and Translational Hepatology. 2021;9(5):731. doi: 10.14218/JCTH.2020.00091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. The American journal of medicine. 1999;107(5):450–455. doi: 10.1016/s0002-9343(99)00271-5. [DOI] [PubMed] [Google Scholar]
- 26.Zhang CH, Zhou BG, Sheng JQ, Chen Y, Cao YQ, Chen C. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res. 2020;159:104984. doi: 10.1016/j.phrs.2020.104984. [DOI] [PubMed] [Google Scholar]
- 27.Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5(1):7–13. doi: 10.15280/jlm.2015.5.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes care. 2007;30(5):1212–1218. doi: 10.2337/dc06-2247. [DOI] [PubMed] [Google Scholar]
- 29.Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397. doi: 10.1053/j.gastro.2015.04.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Souza MRA, Diniz MFFM, Medeiros-Filho JEM, Araújo MST. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arquivos de gastroenterologia. 2012;49:89–96. doi: 10.1590/s0004-28032012000100015. [DOI] [PubMed] [Google Scholar]
- 31.Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert opinion on pharmacotherapy. 2014;15(4):493–503. doi: 10.1517/14656566.2014.876992. [DOI] [PubMed] [Google Scholar]
- 32.Alkhouri N, Eng K, Lopez R, Nobili V. Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD) Springerplus. 2014;3(1):1–9. doi: 10.1186/2193-1801-3-407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Federico A, Dallio M, Masarone M, Persico M, Loguercio C. The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. Eur Rev Med Pharmacol Sci. 2016;20(22):4731–4741. [PubMed] [Google Scholar]
- 34.Mantovani A, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut. 2023;72(7):1433–1436. doi: 10.1136/gutjnl-2022-328224. [DOI] [PubMed] [Google Scholar]
- 35.Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology. 2018;15(7):425–439. doi: 10.1038/s41575-018-0010-0. [DOI] [PubMed] [Google Scholar]
- 36.Wu J, Yao X-Y, Shi R-X, Liu S-F, Wang X-Y. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reproductive Health. 2018;15:1–9. doi: 10.1186/s12978-018-0519-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Spremović Rađenović S, Pupovac M, Andjić M, Bila J, Srećković S, Gudović A, et al. Prevalence, risk factors, and pathophysiology of nonalcoholic fatty liver disease (NAFLD) in women with Polycystic Ovary Syndrome (PCOS) Biomedicines. 2022;10(1):131. doi: 10.3390/biomedicines10010131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrical & gynecological survey. 2004;59(2):141–154. doi: 10.1097/01.OGX.0000109523.25076.E2. [DOI] [PubMed] [Google Scholar]
- 39.Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver–kidney interactions in nonalcoholic fatty liver disease. Trends in molecular medicine. 2015;21(10):645–662. doi: 10.1016/j.molmed.2015.08.005. [DOI] [PubMed] [Google Scholar]
- 40.Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, Smith PL, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology. 2007;45(4):1007–1013. doi: 10.1002/hep.21593. [DOI] [PubMed] [Google Scholar]
- 41.Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obesity Reviews. 2013;14(5):417–431. doi: 10.1111/obr.12020. [DOI] [PubMed] [Google Scholar]
- 42.Cui R, Sheng H, Rui X-F, Cheng X-Y, Sheng C-J, Wang J-Y, et al. Low bone mineral density in Chinese adults with nonalcoholic fatty liver disease. Int J Endocrinol. 2013;2013:396545. 10.1155/2013/396545. [DOI] [PMC free article] [PubMed]
- 43.Eshraghian A, Jahromi AH. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World journal of gastroenterology: WJG. 2014;20(25):8102. doi: 10.3748/wjg.v20.i25.8102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Bikeyeva V, Abdullah A, Radivojevic A, Abu Jad AA, Ravanavena A, Ravindra C, et al. Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know. Cureus. 2022;14(8):e28052. doi: 10.7759/cureus.28052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction? Journal of Thyroid research 2011. 10.4061/2011/152850. [DOI] [PMC free article] [PubMed]
- 46.Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Cmaj. 2005;172(7):899–905. doi: 10.1503/cmaj.045232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Mohamad B, Shah V, Onyshchenko M. Characterization of hepatocellular carcinoma (HCC) in nonalcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int. 2016;10:632–639. doi: 10.1007/s12072-015-9679-0. [DOI] [PubMed] [Google Scholar]
- 48.Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer. 2022;173:250–262. doi: 10.1016/j.ejca.2022.06.051. [DOI] [PubMed] [Google Scholar]
- 49.Corey KE, Rinella ME. Medical and surgical treatment options for nonalcoholic steatohepatitis. Digestive diseases and sciences. 2016;61:1387–1397. doi: 10.1007/s10620-016-4083-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Milovanović T, Pantić I, Dragašević S, Lugonja S, Dumić I, Rajilić-Stojanović M. The interrelationship among non-alcoholic fatty liver disease, colonic diverticulosis and metabolic syndrome. Journal of Gastrointestinal and Liver Diseases. 2021;30(2):1–9. doi: 10.15403/jgld-3308. [DOI] [PubMed] [Google Scholar]
- 51.Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: the good and the bad. Clinical Nutrition. 2014;33(2):186–190. doi: 10.1016/j.clnu.2013.11.003. [DOI] [PubMed] [Google Scholar]
- 52.Lonardo A, Nascimbeni F, Targher G, Bernardi M, Bonino F, Bugianesi E, et al. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease. 2017;49(5):471–483. doi: 10.1016/j.dld.2017.01.147. [DOI] [PubMed] [Google Scholar]
- 53.Dorosti M, Heidarloo AJ, Bakhshimoghaddam F, Alizadeh M. Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial. British Journal of Nutrition. 2020;123(3):328–336. doi: 10.1017/S0007114519002769. [DOI] [PubMed] [Google Scholar]
- 54.Xu C, Markova M, Seebeck N, Loft A, Hornemann S, Gantert T, et al. High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels. Liver International. 2020;40(12):2982–2997. doi: 10.1111/liv.14596. [DOI] [PubMed] [Google Scholar]
- 55.Chitturi S, Wong VWS, Chan WK, Wong GLH, Wong SKH, Sollano J, et al. The Asia–Pacific working party on non-alcoholic fatty liver disease guidelines 2017—part 2: management and special groups. Journal of gastroenterology and hepatology. 2018;33(1):86–98. doi: 10.1111/jgh.13856. [DOI] [PubMed] [Google Scholar]
- 56.Liver EAftSoT, Diabetes EAftSo. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obesity facts. 2016;9(2):65–90. doi: 10.1159/000443344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79–104. doi: 10.1002/hep.23623. [DOI] [PubMed] [Google Scholar]
- 58.Babu AF, Csader S, Lok J, Gómez-Gallego C, Hanhineva K, El-Nezami H, et al. Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. Nutrients. 2021;13(9). [DOI] [PMC free article] [PubMed]
- 59.Slentz CA, Bateman LA, Willis LH, Shields AT, Tanner CJ, Piner LW, et al. Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. American Journal of Physiology-Endocrinology and Metabolism. 2011;301(5):E1033–E10E9. doi: 10.1152/ajpendo.00291.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Oh S, Shida T, Yamagishi K, Tanaka K, So R, Tsujimoto T, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology. 2015;61(4):1205–1215. doi: 10.1002/hep.27544. [DOI] [PubMed] [Google Scholar]
- 61.Ngu M, Norhayati M, Rosnani Z, Maryam M. Curcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: a systematic review and meta-analysis. Complementary Therapies in Medicine. 2022:102843. [DOI] [PubMed]
- 62.Carpi RZ, Barbalho SM, Sloan KP, Laurindo LF, Gonzaga HF, Grippa PC, et al. The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review. International Journal of Molecular Sciences. 2022;23(15):8805. doi: 10.3390/ijms23158805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Wang X, Jin X, Li H, Zhang X, Chen X, Lu K, et al. Effects of various interventions on non-alcoholic fatty liver disease (NAFLD): A systematic review and network meta-analysis. Front Pharmacol. 2023;14:1180016. doi: 10.3389/fphar.2023.1180016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Song L, Zhao XG, Ouyang PL, Guan Q, Yang L, Peng F, et al. Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: A double-blind placebo-controlled clinical trial. British Journal of Nutrition. 2020;123(10):1148–1158. doi: 10.1017/S0007114520000495. [DOI] [PubMed] [Google Scholar]
- 65.Yaghooti H, Ghanavati F, Seyedian SS, Cheraghian B, Mohammadtaghvaei N. The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism. BMC Pharmacology and Toxicology. 2021;22(1):1–9. doi: 10.1186/s40360-021-00485-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Jama. 2007;297(8):842–857. doi: 10.1001/jama.297.8.842. [DOI] [PubMed] [Google Scholar]
- 67.Kavianipour F, Aryaeian N, Mokhtare M, Mirnasrollahiparsa R, Jannani L, Agah S, et al. The effect of saffron supplementation on some inflammatory and oxidative markers, leptin, adiponectin, and body composition in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial. Phytotherapy Research. 2020;34(12):3367–3378. doi: 10.1002/ptr.6791. [DOI] [PubMed] [Google Scholar]
- 68.Fathi M, Alavinejad P, Haidari Z, Amani R. The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Journal of Trace Elements in Medicine and Biology. 2020;62:126635. doi: 10.1016/j.jtemb.2020.126635. [DOI] [PubMed] [Google Scholar]
- 69.Moradi F, Kooshki F, Nokhostin F, Khoshbaten M, Bazyar H, Gargari BP. A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial. Journal of Trace Elements in Medicine and Biology. 2021;63:126659. doi: 10.1016/j.jtemb.2020.126659. [DOI] [PubMed] [Google Scholar]
- 70.Ferro Y, Montalcini T, Mazza E, Foti D, Angotti E, Gliozzi M, et al. Randomized clinical trial: bergamot citrus and wild cardoon reduce liver steatosis and body weight in non-diabetic individuals aged over 50 years. Frontiers in Endocrinology. 2020;11:494. doi: 10.3389/fendo.2020.00494. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Ferro Y, Pujia R, Mazza E, Lascala L, Lodari O, Maurotti S, et al. A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease. Journal of Translational Medicine. 2022;20(1):1–17. doi: 10.1186/s12967-022-03579-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Cicero AFG, Colletti A, Bellentani S. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients. 2018;10(9). [DOI] [PMC free article] [PubMed]
- 73.Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, et al. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. BMJ Open Diabetes Research and Care. 2021;9(1):e001990. doi: 10.1136/bmjdrc-2020-001990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza Babaei M, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Advances in therapy. 2020;37:4697–4708. doi: 10.1007/s12325-020-01498-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Seo H-Y, Lee S-H, Han E, Hwang JS, Han S, Kim MK, et al. Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells. International Journal of Molecular Sciences. 2022;23(19):11636. doi: 10.3390/ijms231911636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Ghosal S, Datta D, Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D) Sci Rep. 2021;11(1):22063. doi: 10.1038/s41598-021-01663-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes research and clinical practice. 2020;170:108487. doi: 10.1016/j.diabres.2020.108487. [DOI] [PubMed] [Google Scholar]
- 78.Lian J, Fu J. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:615409. doi: 10.3389/fendo.2021.615409. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Jin D, Cui Z, Jin S, Zhou T, Guo B, Gao P, et al. Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis. Front Pharmacol. 2022;13:1096064. doi: 10.3389/fphar.2022.1096064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54(5):1610–1619. doi: 10.1002/hep.24544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet. 2015;385(9972):956–965. doi: 10.1016/S0140-6736(14)61933-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. (2013) ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25_suppl_2):S1-S45. [DOI] [PubMed]
- 83.Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology. 2021;74(4):1809–1824. doi: 10.1002/hep.31843. [DOI] [PubMed] [Google Scholar]
- 84.Mosca A, Crudele A, Smeriglio A, Braghini MR, Panera N, Comparcola D, et al. Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD. Digestive and Liver Disease. 2021;53(9):1154–1158. doi: 10.1016/j.dld.2020.09.021. [DOI] [PubMed] [Google Scholar]
- 85.Yoon S, Lee H, Ji SC, Yoon SH, Cho JY, Chung JY. Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function. Clinical Pharmacology in Drug Development. 2021;10(1):68–77. doi: 10.1002/cpdd.790. [DOI] [PubMed] [Google Scholar]
- 86.Xue J, Liang S, Ma J, Xiao Y. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. BMC Endocrine Disorders. 2022;22(1):1–10. doi: 10.1186/s12902-022-00967-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Bahrami M, Cheraghpour M, Jafarirad S, Alavinejad P, Asadi F, Hekmatdoost A, et al. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complementary therapies in medicine. 2020;52:102452. doi: 10.1016/j.ctim.2020.102452. [DOI] [PubMed] [Google Scholar]
- 88.Yasukawa K, Shimizu A, Yokoyama T, Kubota K, Notake T, Seki H, et al. Preventive effect of high-dose digestive enzyme management on development of nonalcoholic fatty liver disease after pancreaticoduodenectomy: a randomized controlled clinical trial. Journal of the American College of Surgeons. 2020;231(6):658–669. doi: 10.1016/j.jamcollsurg.2020.08.761. [DOI] [PubMed] [Google Scholar]
- 89.Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, et al. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. The lancet Gastroenterology & hepatology. 2020;5(11):996–1007. doi: 10.1016/S2468-1253(20)30216-8. [DOI] [PubMed] [Google Scholar]
- 90.Li H, Liu NN, Peng ZG. Effect of bicyclol on blood biomarkers of NAFLD: a systematic review and meta-analysis. BMJ Open. 2020;10(12):e039700. doi: 10.1136/bmjopen-2020-039700. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, et al. TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology. 2021;161(5):1475–1486. doi: 10.1053/j.gastro.2021.07.025. [DOI] [PubMed] [Google Scholar]
- 92.Fouqueray P, Bolze S, Dubourg J, Hallakou-Bozec S, Theurey P, Grouin J-M, et al. Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: a phase 1b study. Cell Reports Medicine. 2021;2(12):100474. doi: 10.1016/j.xcrm.2021.100474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Birnbaum MJ, Calle RA. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial. Med. 2021;2(7):800–813. doi: 10.1016/j.medj.2021.04.007. [DOI] [PubMed] [Google Scholar]
- 94.Shih P-H, Shiue S-J, Chen C-N, Cheng S-W, Lin H-Y, Wu L-W, et al. Fucoidan and fucoxanthin attenuate hepatic steatosis and inflammation of NAFLD through modulation of leptin/adiponectin axis. Marine drugs. 2021;19(3):148. doi: 10.3390/md19030148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Zeybel M, Altay O, Arif M, Li X, Yang H, Fredolini C, et al. Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. Molecular Systems Biology. 2021;17(10):e10459. doi: 10.15252/msb.202110459. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Saneian H, Khalilian L, Heidari-Beni M, Khademian M, Famouri F, Nasri P, et al. Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. Journal of Pediatric Endocrinology and Metabolism. 2021;34(7):897–904. doi: 10.1515/jpem-2020-0642. [DOI] [PubMed] [Google Scholar]
- 97.Draz RS, Serry ZM, Rahmy AF, Ms EB, Taha MM. Electroacupuncture versus aerobic interval training on liver functions in patients with nonalcoholic fatty liver. The Journal of Alternative and Complementary Medicine. 2020;26(1):51–57. doi: 10.1089/acm.2019.0182. [DOI] [PubMed] [Google Scholar]
- 98.Kaufmann B, Reca A, Wang B, Friess H, Feldstein AE, Hartmann D. Mechanisms of nonalcoholic fatty liver disease and implications for surgery. Langenbecks Arch Surg. 2021;406(1):1–17. doi: 10.1007/s00423-020-01965-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Xu G, Song M. Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery. Surg Obes Relat Dis. 2021;17(1):231–238. doi: 10.1016/j.soard.2020.08.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Mingrone G, Van Baar AC, Devière J, Hopkins D, Moura E, Cercato C, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2022;71(2):254–264. doi: 10.1136/gutjnl-2020-323608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Bahirwani R, Griffin C. The diagnosis and management of nonalcoholic fatty liver disease: A patient-friendly summary of the 2018 AASLD guidelines. Clinical Liver Disease. 2022;19(6):222. doi: 10.1002/cld.1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.

